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Background. The chemokine receptor, CCR5, has been identi-
fied as an essential co-receptor with CD4, which permits entry of
human immunodeficiency virus (HIV) into mammalian cells. This
receptor may also mediate leukocyte and parenchymal responses
to injury by virtue of its binding to locally released chemokines
such as RANTES, MIP-1a and MIP-1b during inflammation. The
localization of CCR5 in human or primate kidney is unknown. In
this study we sought to identify sites of CCR5 synthesis through
localization of mRNA coding for this peptide.
Methods. CCR5 cDNA cloned into an expression vector was
transcribed into a 1.1 Kb antisense riboprobe that was utilized for
in situ hybridization (ISH) and Northern blotting studies.
Results. Northern analysis demonstrated positive hybridization for
CCR5 mRNA in total RNA isolated from allograft nephrectomy
tissue with features of severe transplant rejection as well as in kidney
tissue with focal interstitial nephritis. No comparable hybridization
signal was achieved with human kidney tissue uninvolved by disease.
CCR5 mRNA was not identified in intrinsic renal cell types by ISH
in normal human (N 5 6), normal macaque kidney (N 5 5), in
kidneys from macaques with established infection by HIV-2 (N 5 9),
kidneys from macaques infected with HIV-1 (N 5 4), nor in kidneys
from SIV-infected macaques (N 5 5). CCR5 was identified by ISH
in human kidneys with features of interstitial nephritis (N 5 3) and
in rejected human allograft kidneys (N 5 14). The expression of
CCR5 was restricted to infiltrating mononuclear leukocytes at sites of
chronic tubulointerstitial injury and at sites of vascular and interstitial
rejection, respectively.
Conclusions. Understanding the localization of CCR5 as well as
other chemokine receptors may help us understand how specific-
ity in leukocyte trafficking is achieved in renal inflammatory
processes such as allograft rejection and interstitial nephritis.
They provide additional evidence that chemokines may be critical
mediators of leukocyte trafficking in renal allograft rejection.
These findings may account in part for the difficulty in demon-
strating HIV infection of renal cells in human HIV infection, since
these cells appear to lack constitutive expression of an essential
co-receptor needed for viral entry.
A recent review by Schlo¨ndorff et al of chemokine
activity in the kidney began with a fundamental question:
“What determines the type of cellular infiltrate in tissue
injury?” [1]. While many biochemical and physiologic sig-
nals are known to participate in this process, a central role
has emerged which involves an expanding family of small
molecules termed chemokines (chemotactic cytokines). Lo-
calized production and signaling by chemokines controls
infiltration of tissues by specific classes of leukocytes
through interactions with receptors borne by each leuko-
cyte type [2, 3]. Most chemokines have been identified as
belonging to one of two families, C-C and C-X-C, by virtue
of whether or not an amino acid (X) is inserted between the
first two conserved cysteine residues in individual mole-
cules [2, 4]. While there is an apparent overlap in the
binding properties and functions of many of the chemo-
kines, there also appears to be some segregation of func-
tions by families as manifest by the ability of these mole-
cules to recruit specific classes of leukocytes (such as,
monocytes vs. neutrophils) and perhaps mediate some
additional biologic processes such as angiogenesis [2]. The
existence of multiple receptors for chemokines offers a
mechanism by which specificity in directing events in the
inflammatory process by chemokines can be achieved.
The chemokine receptor CCR5 is one member of a
family of structurally and functionally related seven-trans-
membrane-spanning, G-protein-coupled receptors. It is
one of eight CC chemokine receptors that have been
cloned and characterized for their ligand specificity [2, 4, 5].
CCR5 binds to three of the CC-chemokines, namely mac-
rophage inflammatory protein-1 alpha (MIP-1a), macro-
phage inflammatory protein-1 beta (MIP-1b), and RANTES
(regulated upon activation normal T cell expressed and
secreted), but it does not bind monocyte chemoattractant
protein-1 (MCP-1) [6, 7].
1 See Editorial by Klotman, p. 2243.
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Considerable interest in renal expression of chemokines
has proceeded from the recognition that they may mediate
a variety of inflammatory injuries such as allograft rejection
[1]. Recent observations in animal models and in human
biopsy tissue have demonstrated an increased expression of
CC-chemokines in solid organ transplants undergoing allo-
graft rejection. Elevated expression of RANTES has been
demonstrated in renal [8–10] and cardiac [11] allograft
rejection, and the chemokines MIP-1a and MIP-1b were
shown to be elevated in liver allograft rejection [12] and in
the early phase of cardiac rejection [11]. It is likely that
local expression of these chemokines is responsible for the
interstitial and vascular mononuclear cell infiltrates of T
cells and macrophages that characterize renal allograft
rejection [13].
Interest in the chemokines and their receptors also
comes from their recently identified participation in pro-
cesses of cellular infectivity of human immunodeficiency
virus (HIV) [14, 15]. New insights into the pathogenesis of
HIV associated disease have been gained by the recogni-
tion that the chemokine receptor CCR5 serves as a major
co-receptor together with CD4 for macrophage-tropic
strains of HIV-1 in mammalian cells [16–20]. The specific-
ity of T-lymphocyte-tropic strains of HIV-1 appears to
result from their requirement for binding to the chemokine
receptor CXCR4 as a condition of entry into mammalian
cells [21, 22]. Expression of these molecules appears to be
a key to understanding whether tissues are permissive for
direct HIV infection. This has been substantiated by obser-
vations that genetic mutation of these molecules is a major
impediment to HIV infection in individuals exposed to this
virus [23–25].
In this study, we provide information on the cellular sites
of synthesis of one chemokine receptor, CCR5, in mature
adult human and primate kidneys, and in kidneys involved
in allograft rejection and in immunodeficiency virus infec-
tion. In the case of renal allograft rejection, despite the
growing numbers of reports on the role of chemokines in
the rejection process, nothing is known about the expres-
sion of the corresponding receptors. We therefore studied
whether a role for CCR5, the receptor for MIP-1a, MIP-1b
and RANTES could be inferred in human renal allograft
rejection.
Renal localization of CCR5 also has significance for
understanding the pathogenesis of HIV nephropathy. It is
still unknown whether the presence of intact virus or viral
proteins within the renal parenchyma is required for the
development of this nephropathy [26–28]. It has been
proposed that HIV may directly infect renal parenchymal
cells, although the data are conflicting. Biological hetero-
geneity in the strains of HIV-1 have been postulated to
account for a particular “nephritogenic” strain [26]. HIV-1
strains isolated during the period of acute infection or from
asymptomatic individuals are more often macrophage-
tropic, whereas isolates from patients with fully developed
AIDS are more often T-tropic or both macrophage and
T-tropic. It has been hypothesized that macrophage-tropic
strains characteristic of early disease states have a greater
capacity to produce nephropathy [26]. We address the
question as to whether or not CCR5, the major coreceptor
for macrophage-tropic HIV-1 strains, is constitutively ex-
pressed by intrinsic renal cells in the belief that this would
help our understanding of which cell types might be
permissive for direct infection. Because non-human pri-
mates infected with simian immunodeficiency virus (SIV)
[29] or, in some cases, with HIV-2, may be a model for
human HIV associated nephropathy (HIVAN), we also
sought to detect CCR5 mRNA expression in control and
immunodeficiency virus infected primate tissues as well.
METHODS
Source of tissue
Normal human kidney tissue (N 5 9) was obtained from
kidneys surgically excised because of the presence of a
localized neoplasm. Tissues utilized for this study were
obtained from macroscopically normal portions of kidney
located at some distance from the neoplastic process. Three
of the nine kidneys showed the microscopic presence of
focal interstitial nephritis with chronic tubulointerstitial
injury and were subsequently regarded as a separate group.
Normal kidneys from pig-tailed macaques, Macaca nemes-
trina (N 5 5), sacrificed in the course of studies that did not
involve initiation of disease processes, were obtained from
the Regional Primate Research Center at the University of
Washington.
In addition to these normal human and non-human
primate kidneys, kidneys of macaques infected with differ-
ent immunodeficiency virus strains were also utilized. Kid-
ney tissue from pig-tailed macaques, Macaca nemestrina,
infected with SIVMne (N 5 5) [29], type D retrovirus (N 5
5) [29], HIV-2/287 (N 5 9) [30], and HIV-1 (N 5 4) [31, 32]
were analyzed in this study. The detailed protocols for
these studies have been published previously [29–32].
Animals were monitored for viremia and clinical disease.
Animals developing an AIDS-like illness were euthanized
when they were no longer able to be supported humanely
by conventional veterinary care.
Human allograft nephrectomies (N 5 14) excised for
irreversible rejection were also utilized. All cases had
features of severe cellular (interstitial) and vascular rejec-
tion. Many of these nephrectomy specimens also contained
occasional, irregularly distributed lymphoid aggregates sim-
ilar to those previously described in other solid organ
allografts. The nephrectomy specimens in general were
exposed to multiple courses of routine and intensified
immunosuppression prior to excision, and represent a
heterogenous sample from a clinical standpoint.
Portions of these tissues were fixed in 10% phosphate-
buffered formalin, embedded in paraffin and sectioned.
Additionally, unfixed tissue samples of normal human
kidney, normal macaque kidney, spleen, and mesenteric
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lymph node and human allograft nephrectomies were
stored at 270°C prior to isolation of total RNA.
Cell lines
To confirm the specificity of the CCR5 riboprobe, che-
mokine receptor transfected cell lines were used as con-
trols. HOS cells expressing CCR1, CCR2B, CCR3, CCR4,
CCR5, or CXCR4 were obtained through the AIDS Re-
search and Reference Reagent Program, Division of AIDS,
NIAID, NIH from Dr. Nathaniel Landau [16, 33]. The cells
were grown in DMEM medium (Sigma, St. Louis, MO,
USA), supplemented with 10% fetal bovine serum and 0.5
mg/ml puromycin (Fluka, Ronkonkoma, NY, USA). After
reaching confluency, the cells were trypsinized and centri-
fuged. The resulting cell pellets were either fixed in 10%
phosphate-buffered formalin, paraffin embedded and ana-
lyzed by in situ hybridization or used for total RNA
isolation.
Molecular probes
The CCR5 expression vector was obtained through the
AIDS Research and Reference Reagent Program (Division
of AIDS, NIAID, NIH from Dr. Nathaniel Landau) and
has been characterized previously [16, 34]. The 1.1 Kb
insert was derived from cDNA encoding CCR5, and cloned
into pcDNAI/amp (Invitrogen, Carlsbad, CA, USA).
The plasmid was cut with appropriate restriction en-
zymes and transcribed into antisense and sense riboprobes,
using reagents from Promega (Madison, WI, USA), except
[35S]-uridine triphosphate (UTP), which was obtained from
New England Nuclear (Boston, MA, USA). The transcrip-
tion reaction mixture contained 1 mg of CCR5 cDNA
(sense or antisense orientation), 250 mCi of [35S]-UTP, 500
mmol/liter each of adenosine 59-trisphosphate (ATP), cyti-
dine 59-triphosphate (CTP) and guanosine 59-triphosphate
(GTP), 40 U of RNAsin, 10 mmol/liter dithiothreitol, 40
mmol/liter Tris and 10 U of either SP6 or T7 polymerase.
After incubating 75 minutes at 37°C, the template DNA
was digested by adding 1 U of RQ1 DNAse (Promega) and
incubated at 37°C for an additional 15 minutes. Free
nucleotides were separated with a Sephadex G-50 column.
The collected fraction containing labeled probe was then
ethanol precipitated. The probe was resuspended in nucle-
ase free water containing 10 mmol dithiothriotol, counted
and used within 48 hours. The CCR5 antisense riboprobe
generated for the Northern analysis was labeled with
[32P]-UTP (New England Nuclear).
A 1.7 kb sequence of DNA coding for HIV-2 gp120 (env)
(nucleotides 6480-8335 of the HIV-2/287 sequence), cloned
into pCR II (Invitrogen), was kindly provided by Bristol-
Myers Squibb (Seattle, WA, USA). Antisense and sense
riboprobes were generated for in situ hybridization follow-
ing the above mentioned protocol. Specificity of the HIV-2
gp120 riboprobe was established by in situ hybridization.
PBMC from HIV-2/287 infected macaques and from unin-
fected macaques were fixed in formalin, paraffin embedded
and sections of the fixed PBMC pellets were analyzed by in
situ hybridization. Positive hybridization with the HIV-2/287
gp120 antisense probe could be detected only for the cells
from HIV-2 infected animals. Furthermore, no hybridiza-
tion signal was demonstrable on lymph nodes obtained
from uninfected, normal macaques (N 5 5).
The pTRI-RNA-28S antisense control template contain-
ing a 115 bp cDNA fragment of the human 28S rRNA gene
was purchased from Ambion (Austin, TX, USA). Run-off
transcripts to total RNA detect the 4,718 nucleotide 28S
rRNA species in a Northern blot. The in vitro transcription
reaction was performed with Digoxigenin-labeled UTP
(Boehringer Mannheim, Indianapolis, IN, USA) and T7
polymerase.
In situ hybridization
Tissue and cells were fixed in 10% neutral buffered
formalin and embedded in paraffin, sectioned, and depar-
affinized following standard protocols which we have pre-
viously utilized [35, 36]. The sections were washed with
0.5 3 standard saline citrate (SSC) (1 3 SSC 5 150 mM
NaCl, 15 mM Na citrate, pH 7.0) and digested with protein-
ase K (5 mg/ml; Sigma) in Tris buffer for 30 minutes at
37°C. Several 0.5 3 SSC washes were followed by prehy-
bridization for two hours in 100 ml of prehybridization
buffer (0.3 M NaCl, 20 mM Tris pH 8.0, 5 mM EDTA, 1 3
Denhardt’s solution, 10% dextran sulfate, 10 mM DTT).
The hybridizations were started by adding 500,000 cpm of
35S-labeled riboprobe in 50 ml of prehybridization buffer
and allowed to proceed overnight at 50°C. After hybridiza-
tion, sections were washed with 0.5 3 SSC, treated with
RNase A (20 mg/ml, 30 min at 37°C), washed in 2 3 SSC
(2 3 2 min), followed by three high-stringency washes in
0.1 3 SSC/0.5% Tween 20 (Sigma) for 40 minutes each at
50°C, and several 2 3 SSC washes. After the tissue was
dehydrated and air-dried, it was dipped in NTB2 nuclear
emulsion (Kodak, Rochester, NY, USA) and exposed in
the dark at 4°C for four weeks (CCR5), or two weeks
(HIV-2), respectively. After developing, the sections were
counterstained with hematoxylin and eosin, dehydrated and
coverslipped.
RNA isolation
Total RNA was extracted from frozen tissue and chemo-
kine receptor transfected cell lines, respectively, using the
Total RNA Isolation Kit (Ambion).
Briefly, unfixed frozen tissue was disrupted by grinding it
to a powder and then it was denatured using a tissue
homogenizer (Tissumizer SDT-1810; Teckmar, Cincinnati,
OH, USA). Following phenol/chloroform extraction, the
RNA was recovered by isopropanol precipitation. Remain-
ing salt was removed by ethanol wash and residual carbo-
hydrate by lithium chloride precipitation. Finally, the pel-
lets were resuspended in RNase-free water. The RNA
concentration was measured by reading the absorbance in a
spectrophotometer at the wavelength of 260 nm. The
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intactness and overall quality of the total RNA preparation
was assessed by electrophoresis on a native agarose gel
demonstrating sharp and intense 28S and 18S ribosomal
bands.
Northern analysis
Samples (10 mg RNA) were electrophoresed through a
1% agarose-formaldehyde gel and transferred to a posi-
tively charged nylon membrane (BrightStar-Plus; Ambion).
Blots were hybridized overnight with the [32P]-UTP labeled
CCR5 riboprobe as described previously and exposed in
the dark at 270°C for 10 days. To confirm the intactness
and total amount of the blotted RNA the membranes were
subsequently stripped and hybridized with the Digoxigenin-
UTP labeled 28S riboprobe, using the Northern Max
Northern blotting kit (Ambion).
RESULTS
Molecular probe
Specificity of the CCR5 antisense riboprobe was estab-
lished by Northern analysis and in situ hybridization. Total
RNA isolated from HOS cell lines transfected with DNA
coding for CCR5, CCR1, CCR2B, CCR3, CCR4, and
CXCR4 respectively was generated for Northern analysis.
Positive hybridization with the CCR5 riboprobe could only
be detected for the CCR5 transfected cell line showing a
single band at the expected 4.0 kilobase size of CCR5
mRNA (Fig. 1). No nonspecific crosshybridization with
RNA isolated from the several control cell lines could be
detected.
Paraffin embedded cell pellets of the CCR5 transfected
HOS cell line and of similar cell lines transfected with
CCR1, CCR2B, CCR3, CCR4 and CXCR4 respectively
were utilized for in situ hybridization. Positive hybridization
with the CCR5 antisense probe was demonstrable on the
CCR5 cell line (Fig. 2A), but not on any of the other cell
lines transfected with different chemokine receptors (data
not shown). Additional negative controls included the
absence hybridization when identical procedures were per-
formed with substitution of a sense probe for hybridization
(Fig. 2B).
Normal kidneys
CCR5 mRNA was undetectable by Northern analysis in
total RNA isolated from normal human (Fig. 3) and
macaque (data not shown) kidneys, respectively. This result
was confirmed by in situ hybridization for CCR5 mRNA in
formalin fixed paraffin embedded normal kidney tissue. In
situ hybridization showed the presence of a very small
number of CCR5 mRNA expressing cells in normal human
kidneys (Fig. 4A). Those cells, which appeared to be
leukocytes, were localized in the interstitium, at times
demonstrable within the lumina of peritubular capillaries.
No cells which could be clearly identified as intrinsic renal
cells within the glomerular, tubular, interstitial, or vascular
compartments showed positive hybridization for CCR5.
CCR5 mRNA expression was completely absent in normal
Fig. 1. CCR5 Northern blot of transfected HOS cell lines demonstrating
specificity of the probe for CCR5 mRNA. Ten micrograms of total RNA,
isolated from different chemokine receptor transfected cell lines, were
electrophoresed and blotted as described in the methods section. Hybrid-
ization with the CCR5 riboprobe (top) detects a single band at the
expected size of 4.0 kilobase only in RNA isolated from CCR5 transfected
cells. Hybridization for 28S rRNA (bottom) demonstrates comparable
amounts of total RNA in each lane.
Fig. 2. In situ hybridization of transfected HOS cell lines demonstrating
specificity of the probe for CCR5 mRNA. (A) Positive hybridization with
the CCR5 antisense riboprobe is demonstrable on a formalin fixed,
paraffin embedded pellet of CCR5 transfected HOS cells. (B) No hybrid-
ization of the control CCR5 sense riboprobe is detectable on the same
CCR5 transfected cell pellet.
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macaque kidneys by in situ hybridization (data not shown).
Three of the macroscopically normal kidneys utilized dem-
onstrated the mild nephrosclerosis characteristic of aging
kidneys as well as the focal interstitial inflammation typi-
cally associated with renal fibrosis, and were considered as
a separate group. Northern analysis detected a weak hy-
bridization signal for CCR5 mRNA in the RNA isolated
from one human kidney with such interstitial inflammation
(Fig. 3). By in situ hybridization CCR5 mRNA expression
was occasionally demonstrable at sites of leukocytic infil-
tration associated with chronic tubulointerstitial injury
(Fig. 4B). The hybridization signal was confined to infiltrat-
ing mononuclear cells and could not be detected on tubular
or glomerular cells or on vascular endothelium.
Animal models of AIDS
The CCR5 antisense probe utilized in this study was
originally generated against human CCR5. We were able to
show that this riboprobe also detects non-human primate
CCR5. In situ hybridization demonstrated the presence of
CCR5 expressing cells in lymph node (Fig. 5A) and spleen
(data not shown) tissue isolated from HIV-2 infected
macaques. The expression of the chemokine receptor
CCR5 correlated with HIV-2 infection of macaque lymph
nodes, as shown by positive in situ hybridization for HIV-2
gp120 RNA in sequential sections of the same lymph node
(Fig. 6).
In kidneys of HIV-2 (N 5 9) or HIV-1 (N 5 4) infected
macaques, hybridization for CCR5 mRNA was completely
absent (Fig. 5B). None of these animals showed specific
renal pathologic lesions similar to those described in HIV-
infected humans. Kidneys obtained from SIVMne and type
D retrovirus infected macaques also revealed the absence
of CCR5 mRNA hybridization signal by in situ hybridiza-
tion (data not shown).
Human renal allograft rejection
Northern analysis detected CCR5 mRNA in total RNA
isolated from the one allograft nephrectomy studied in this
manner (Fig. 3). The histopathological evaluation of this
kidney demonstrated features of severe cell-mediated
transplant rejection. All fourteen allograft nephrectomies
included in this study demonstrated severe cell-mediated
transplant rejection with variable degrees of vascular rejec-
tion. This was characterized by diffuse, at times massive,
interstitial mononuclear cell infiltrates and arterial intimal
proliferative changes with inflammatory cell infiltration as
previously described and illustrated [35]. CCR5 mRNA
expressing cells were detectable in all observed allograft
nephrectomies, but were variable in number in the differ-
ent cases (Fig. 7 A, C). Nine nephrectomies exhibited a
large number of CCR5 mRNA expressing cells, and in five
kidneys the number of such cells was relatively few.
Fig. 3. CCR5 Northern blot of different kidney tissues. Ten micrograms
of total RNA, isolated from frozen kidney tissue, were electrophoresed
and blotted as described in the Methods section. CCR5 mRNA is detected
in total RNA isolated from one human allograft nephrectomy, and a weak
band is present in total RNA isolated from one human kidney with
features of focal interstitial nephritis. Normal human kidney RNA shows
no detectable hybridization signal for CCR5 mRNA. The positive control
was performed on the same membrane and shows hybridization for RNA
isolated from CCR5 transfected cells. Control hybridization for 28S rRNA
(bottom) was performed on the same membrane and confirmed compa-
rable amounts of loaded total RNA.
Fig. 4. CCR5 expression in native human kidney. (A) Very few CCR5
mRNA expressing cells are detectable in normal human kidneys. In situ
hybridization for CCR5 mRNA shows occasional positive mononuclear
cells in the lumina of peritubular capillaries and in the interstitium
(arrow). (B) Human kidneys with features of focal interstitial inflamma-
tion demonstrate CCR5 mRNA expression at sites of leukocytic infiltra-
tion. CCR5 mRNA is not detectable in the glomerular (G) or tubular (T)
compartment. Original magnification 31000.
Eitner et al: CCR5 expression in the kidney 1949
The expression of CCR5 was restricted to infiltrating
mononuclear cells. A few CCR5 positive cells were de-
tected in the capillary lumina of some glomeruli (Fig. 7B),
but CCR5 mRNA expression by intrinsic glomerular cells
could not be detected. Hybridization signal for CCR5
mRNA was absent in tubular cells and in endothelial cells.
In nephrectomies with additional features of vascular re-
jection, some neointimal cells showed CCR5 mRNA ex-
pression (Fig. 7E). Assessment of whether these cells
expressing CCR5 mRNA were infiltrating macrophages/
lymphocytes or neointimal smooth muscle cells was not
possible in these cases, because of technical limitations we
have encountered with the sensitivity of the radioactive
hybridization technique using this particular CCR5 probe.
The sensitivity of this procedure becomes markedly com-
promised when additional immunohistochemical double
labeling procedures are added.
DISCUSSION
We were unable to demonstrate constitutive expression
of the chemokine receptor CCR5 in intrinsic renal cells
using a riboprobe with specificity for CCR5 mRNA. Nei-
ther normal human or macaque kidneys nor kidneys ob-
tained from macaques infected with several different im-
munodeficiency viruses demonstrated CCR5 mRNA
expression. However, we were able to detect for the first
time the presence of CCR5 expressing cells in the kidney, in
the setting of various inflammatory disease processes. We
detected CCR5 at sites of leukocytic infiltration in cases of
focal interstitial nephritis and in renal allograft nephrecto-
mies with features of severe transplant rejection.
Fig. 5. CCR5 expression in the HIV-2 infected macaque. (A) CCR5
antisense riboprobe also detects non-human primate CCR5 mRNA.
CCR5 expressing cells are detected in mesenteric lymph nodes isolated
from pig-tailed macaques infected with HIV-2/287. (B) CCR5 mRNA is
not detected in renal parenchyma of macaques infected with different
immunodeficiency viruses. In situ hybridization for CCR5 mRNA showed
no positive cell in a kidney of a HIV-2/287 infected pig-tailed macaque.
Original magnification 31000.
Fig. 6. HIV-2 RNA in infected macaque lymph nodes is demonstrable in
lymph nodes expressing CCR5 mRNA. (A) In situ hybridization for
HIV-2/287 gp120 RNA detects HIV-2 infected cells in mesenteric lymph
nodes of HIV-2/287 infected macaques, seen at higher magnification in (B).
This is a sequential section of the same lymph node illustrated in Figure
5A. (C) Absent hybridization on the same HIV-2 infected mesenteric
lymph node is demonstrable with substitution of a sense probe for
hybridization. Original magnification A and C 3100, B 3400.
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Chemokines and the corresponding receptors play a
central role in regulation of inflammatory processes [2, 3,
37, 38]. To further define a possible role of the chemokine
receptor CCR5 in renal inflammatory disease we studied
the expression of CCR5 mRNA in renal allograft rejection.
Cell-mediated transplant rejection is represented by an
interstitial mononuclear infiltrate of T cells, macrophages,
and occasionally eosinophils [13]. Several studies reported
an elevated expression of the CCR5 ligands RANTES,
MIP-1a and MIP-1b in solid organ transplants with fea-
tures of cell-mediated rejection [8–12]. It has been hypoth-
esized that infiltrating mononuclear cells and intrinsic
parenchymal cells within inflammatory foci locally express
specific chemokines. These chemokines may then be re-
sponsible for inducing adhesive interactions between roll-
ing leukocytes and the endothelium, subsequently attract-
ing diapedesing leukocytes to specific tissue sites of
inflammation by a chemokine concentration gradient [3, 38,
Fig. 7. CCR5 expression in human renal allograft rejection. (A) CCR5 mRNA expression is detectable in all observed allograft nephrectomies and is
restricted to infiltrating mononuclear cells in the interstitium and in rejecting arteries. Tubular cells do not demonstrate a positive CCR5 hybridization
signal. (B) A small number of CCR5 positive cells can be detected in the capillary lumina of some glomeruli (arrow), but intrinsic glomerular cells do
not show a hybridization signal for CCR5 mRNA. (C) A large number of CCR5 mRNA expressing cells is detectable at sites of interstitial mononuclear
cell infiltrates. (D) No hybridization signal of the CCR5 sense control riboprobe is detectable on a cellular infiltrate of the same human allograft
nephrectomy. (E) Allograft nephrectomies with additional features of vascular rejection occasionally demonstrate some CCR5 mRNA expressing
neointimal cells. The area between arrows is illustrated in higher power in panel F. (F) Examples of CCR5 mRNA expressing neointimal cells in a
rejecting artery are indicated by arrows. CCR5 mRNA expression is also demonstrable in several mononuclear cells within the perivascular/adventitial
infiltrate illustrated in E. Abbreviations are: L, lumen; I, neointima; A, adventitia. Original magnification A-D and F 31000, E 3400.
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39]. Specificity is achieved by virtue of the ability of the
chemokines produced at a given site of injury to bind to
specific receptors, such as CCR5, borne on the surface of
different classes of leukocytes.
This study demonstrates the presence of CCR5 express-
ing cells in renal allograft rejection using two complemen-
tary approaches. Northern analysis demonstrated an in-
tense hybridization signal for CCR5 mRNA in a kidney
with severe transplant rejection. This initial result was
confirmed by in situ hybridization studies. All observed
cases with the diagnosis of severe transplant rejection
exhibited an increased expression of CCR5 mRNA. The
presence of this chemokine receptor was restricted to
infiltrating mononuclear cells and was not seen on intrinsic
renal cells. We did observe variability in the extent of
synthesis of CCR5 mRNA between kidneys with similar
degrees of inflammatory cell infiltration. While we have no
data that would clearly account for this observation, some
possibilities include irregular synthesis of CCR5 (that is,
discontinuous vs. steady-state production) and the possibil-
ity that other chemokine receptors may be more important
in mediating sites of inflammatory cell aggregation in some
allograft kidneys, as discussed below. Our observations in
allograft kidneys are supported by the related observation
that CCR5 mRNA expression is also detectable in infiltrat-
ing inflammatory cells in kidneys with features of focal
interstitial nephritis.
Immunohistochemistry for CCR5 protein performed by
Rottman et al in one kidney with features of interstitial
nephritis showed positive staining for rare interstitial
mononuclear cells and also arteriolar endothelial and vas-
cular smooth muscle cells [40]. Using the alternate techni-
cal approach of in situ hybridization, we were unable to
show CCR5 mRNA expression on either endothelial or
vascular smooth muscle cells in this study. The monoclonal
antibody against CCR5 protein used by Rottman et al was
not available for our study.
One other recent study focused on chemokine receptor
expression in kidney tissue. Schadde et al detected CCR 1,
2, 3, and 5 in RNA isolated from normal mouse kidneys by
quantitative RT-PCR [41]. After experimental induction of
an anti-glomerular basement membrane nephritis in these
mice, an increase of mRNA expression for CCR1, 2, 3, and
5 was detected. Due to the lack of a morphological
correlate in the design of this study one cannot determine
whether some or all of the increased chemokine receptor
expression reflects an increased number of chemokine
receptor expressing infiltrating macrophages and/or lym-
phocytes involved in the pathogenesis of this glomerulone-
phritis, or is the result of de novo production by renal
parenchymal cells.
Further studies focusing on the role of other chemokine
receptors are necessary to understand the complicated
network of leukocyte attraction in the pathogenesis of renal
transplant rejection. Although we were able to detect a
strong expression of CCR5 mRNA in most kidneys with
severe allograft rejection, it is important to point out that a
large percentage of infiltrating leukocytes did not express
CCR5. It is likely that different chemokine receptors are
expressed on CCR5 negative infiltrating cells. An up-
regulated expression of another CC-chemokine, monocyte
chemoattractant protein-1 (MCP-1) has also been demon-
strated in renal allograft rejection [42, 43]. MCP-1 is a
ligand for CCR2 and CCR4 [2, 4]. To our knowledge, no
study has analyzed the expression of these chemokine
receptors in renal allograft rejection. With better definition
of chemokine mediated leukocyte trafficking events, we
believe new therapeutic approaches in renal allograft re-
jection using anti-chemokine agents may be envisioned.
The second component of this study bears on the role of
CCR5 in the pathogenesis of HIV associated injury. During
the past two years, chemokine receptors have been identi-
fied as essential co-receptors for human immunodeficiency
virus infection [14, 15]. Macrophage-tropic strains of HIV-1
involved in the initial infection phase utilize CCR5 as a
major co-factor. The binding of HIV-1 envelope protein
gp120 to the cell surface receptors CD4 and chemokine
receptor CCR5 subsequently permits entry of HIV-1 into
the cell [14, 15]. CCR3 and CCR2B have similar functions,
but their role as co-receptors is less prominent, suggesting
that viral envelope proteins have lower affinity for these
receptors. T lymphocyte-tropic strains of HIV-1 isolated
from patients with clinical AIDS more frequently utilize
CXCR4 as infection co-receptor. The involvement of che-
mokine receptors in the infection process has been further
supported by in vitro inhibition studies. Infection of mac-
rophage-tropic HIV-1 strains can be suppressed by the
CCR5 ligands MIP-1a, MIP-1b and RANTES [17, 19, 44],
and the CXCR4 ligand SDF-1 was found to be a potent
inhibitor of infection by T-tropic HIV-1 strains [45, 46].
Although all of the initial reports on chemokine recep-
tors as HIV co-receptors represent in vitro findings, further
in vivo observations support the role of this receptor family
in the pathogenesis of HIV infection. A mutant allele of the
CCR5 gene bearing a 32-nucleotide deletion (CCR5 delta
32) has recently been characterized [23, 24] and individuals
homozygous for this allele have been linked to protection
from HIV-1 infection [47, 48]. The consequence of the
heterozygous state is not clear, but it may delay the
progression to AIDS in infected individuals [47–49].
HIV-associated nephropathy is a unique disease that can
be seen in up to 10% of some HIV-infected populations.
Characteristic histologic features of HIV-associated ne-
phropathy (HIVAN) include a collapsing form of focal and
segmental glomerulosclerosis and microcystic dilation of
renal tubules [26, 28]. Whether the glomerulopathy that
occurs in HIVAN may be a direct consequence of infection
with HIV or a result of exposure to select viral peptides or
whether it may be due to other factors independently
present in certain patient populations is unknown. While
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there is evidence from a single publication that HIV can
directly infect renal parenchyma as demostrated by in situ
hybridization [50], we (unpublished observations) and oth-
ers [50, 51] have not been able to replicate this result. In
previous studies we have not identified specific antigens or
messenger RNA of HIV (unpublished observations) or SIV
[29] in renal parenchymal cells in primate models of
immunodeficiency virus infection. Investigations into the
infectivity of human glomerular cells in vitro have yielded
conflicting results. We have been unable to demonstrate
productive infection of human mesangial cells by either
T-tropic or macrophage-tropic strains of HIV-1 and HIV-2
[53]. One other group has reported HIV infectivity in vitro
of human glomerular endothelial cells and a small propor-
tion of mesangial cells but not epithelial cells [54]. How-
ever, the experimental design of that study suggested the
possibility of transfection rather than infection of renal
cells.
This present study sought to detect the expression of the
HIV co-receptor CCR5 in normal kidneys and in kidneys
obtained from primates infected with different immunode-
ficiency viruses. In situ hybridization failed to detect expres-
sion of CCR5 mRNA on renal parenchymal cells in normal
human and non-human primate kidneys. A small number
of CCR5 expressing cells could be seen in normal kidney
tissue within the lumina of peritubular capillaries and
showed morphological features of lymphocytes or mono-
cytes. There was no evidence for the presence of CCR5
mRNA on mesangial cells, vascular endothelial cells, vas-
cular smooth muscle cells, glomerular epithelial cells or
interstitial fibroblasts. No CCR5 mRNA expression in
primate kidneys was detectable when inflammatory cells
were absent.
The absent expression and/or detection of CCR5 mRNA
in uninfected normal renal tissue does not exclude a role
for CCR5 in HIV-associated renal disease. An up-regula-
tion of chemokine receptor expression might be detectable
in disease states. We therefore additionally investigated
whether CCR5 could be detected in animal models of
AIDS. The riboprobe generated against human CCR5
crossreacts with non-human primate CCR5. Pig-tailed ma-
caques infected with HIV-1 [31, 32] and a strain of HIV-2
(HIV-2/287) [30] that induces an AIDS-like disease failed to
develop specific renal pathologic lesions similar to those of
HIVAN (F. Eitner, unpublished observations). Further-
more, we were not able to detect CCR5 mRNA expression
in the kidney of HIV-1 or HIV-2 infected macaques, nor in
the kidney of SIVMne infected macaques [29]. Perhaps as a
consequence of absent parenchymal expression of CCR5,
we found that kidney tissue of these primates infected with
HIV-2 exhibited no messenger RNA encoding for HIV-2
viral proteins as demonstrated by in situ hybridization
(manuscript in preparation), indicating the absence of
parenchymal infection. We believe this failure to detect
specific viral RNA and CCR5 mRNA in renal parenchyma
of macaques infected with different immunodeficiency vi-
ruses provides additional insight into the difficulty encoun-
tered in attempts to demonstrate direct infection of intrin-
sic renal cells by immunodeficiency viruses.
ACKNOWLEDGMENTS
This work was supported in part by grants DK 49514, DK 47659, RR
00166 from the National Institutes of Health. Provision of reagents by the
AIDS Research and Reference Reagent Program of the NIAID, NIH is
gratefully acknowledged.
Reprint requests to Frank Eitner, M.D., University of Washington, Depart-




1. SCHLO¨NDORFF D, NELSON PJ, LUCKOW B, BANAS B: Chemokines and
renal disease. Kidney Int 51:610–621, 1997
2. ROLLINS BJ: Chemokines. Blood 90:909–928, 1997
3. FURIE MB, RANDOLPH GJ: Chemokines and tissue injury. Am J Pathol
146:1287–1301, 1995
4. BAGGIOLINI M, DEWALD B, MOSER B: Human chemokines: An
update. Annu Rev Immunol 15:675–705, 1997
5. YOSHIE O, IMAI T, NOMIYAMA H: Novel lymphocyte-specific CC
chemokines and their receptors. J Leukoc Biol 62:634–644, 1997
6. RAPORT CJ, GOSLING J, SCHWEICKART VL, GRAY PW, CHARO IF:
Molecular cloning and functional characterization of a novel human
CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and
MIP-1alpha. J Biol Chem 271:17161–17166, 1996
7. SAMSON M, LABBE O, MOLLEREAU C, VASSART G, PARMENTIER M:
Molecular cloning and functional expression of a new human CC-
chemokine receptor gene. Biochemistry 35:3362–3367, 1996
8. PATTISON J, NELSON PJ, HUIE P, VON LEUTTICHAU I, FARSHID G,
SIBLEY RK, KRENSKY AM: RANTES chemokine expression in cell-
mediated transplant rejection of the kidney. Lancet 343:209–211, 1994
9. NAGANO H, NADEAU KC, TAKADA M, KUSAKA M, TILNEY NL:
Sequential cellular and molecular kinetics in acutely rejecting renal
allografts in rats. Transplantation 63:1101–1108, 1997
10. STREHLAU J, PAVLAKIS M, LIPMAN M, SHAPIRO M, VASCONCELLOS L,
HARMON W, STROM TB: Quantitative detection of immune activation
transcripts as a diagnostic tool in kidney transplantation. Proc Natl
Acad Sci USA 94:695–700, 1997
11. FAIRCHILD RL, VANBUSKIRK AM, KONDO T, WAKELY ME, OROSZ
CG: Expression of chemokine genes during rejection and long-term
acceptance of cardiac allografts. Transplantation 63:1807–1812, 1997
12. ADAMS DH, HUBSCHER S, FEAR J, JOHNSTON J, SHAW S, AFFORD S:
Hepatic expression of macrophage inflammatory protein-1 alpha and
macrophage inflammatory protein-1 beta after liver transplantation.
Transplantation 61:817–825, 1996
13. PORTER KA: Acute tubulointerstitial rejection (acute cellular rejec-
tion), in Pathology of the Kidney (vol 3), edited by HEPTINSTALL RH,
Boston, Little, Brown and Company, 1992, pp 1839–1853
14. MOORE JP, TRKOLA A, DRAGIC T: Co-receptors for HIV-1 entry. Curr
Opin Immunol 9:551–562, 1997
15. BRODER CC, COLLMAN RG: Chemokine receptors and HIV. J Leukoc
Biol 62:20–29, 1997
16. DENG H, LIU R, ELLMEIER W, CHOE S, UNUTMAZ D, BURKHART M,
DI MARZIO P, MARMON S, SUTTON RE, HILL CM, DAVIS CB, PEIPER
SC, SCHALL TJ, LITTMAN DR, LANDAU NR: Identification of a major
co-receptor for primary isolates of HIV-1. Nature 381:661–666, 1996
17. DRAGIC T, LITWIN V, ALLAWAY GP, MARTIN SR, HUANG Y, NA-
GASHIMA KA, CAYANAN C, MADDON PJ, KOUP RA, MOORE JP,
PAXTON WA: HIV-1 entry into CD41 cells is mediated by the
chemokine receptor CC-CKR-5. Nature 381:667–673, 1996
18. CHOE H, FARZAN M, SUN Y, SULLIVAN N, ROLLINS B, PONATH PD,
WU L, MACKAY CR, LAROSA G, NEWMAN W, GERARD N, GERARD C,
SODROSKI J: The beta-chemokine receptors CCR3 and CCR5 facili-
tate infection by primary HIV-1 isolates. Cell 85:1135–11348, 1996
Eitner et al: CCR5 expression in the kidney 1953
19. ALKHATIB G, COMBADIERE C, BRODER CC, FENG Y, KENNEDY PE,
MURPHY PM, BERGER EA: CC CKR5: A RANTES, MIP-1alpha,
MIP-1beta receptor as a fusion cofactor for macrophage-tropic
HIV-1. Science 272:1955–1958, 1996
20. DORANZ BJ, RUCKER J, YI Y, SMYTH RJ, SAMSON M, PEIPER SC,
PARMENTIER M, COLLMAN RG, DOMS RW: A dual-tropic primary
HIV-1 isolate that uses fusin and the beta-chemokine receptors
CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149–1158,
1996
21. FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry
cofactor: Functional cDNA cloning of a seven-transmembrane, G
protein-coupled receptor. Science 272:872–877, 1996
22. BERSON JF, LONG D, DORANZ BJ, RUCKER J, JIRIK FR, DOMS RW: A
seven-transmembrane domain receptor involved in fusion and entry of
T-cell-tropic human immunodeficiency virus type 1 strains. J Virol
70:6288–6295, 1996
23. LIU R, PAXTON WA, CHOE S, CERADINI D, MARTIN SR, HORUK R,
MACDONALD ME, STUHLMANN H, KOUP RA, LANDAU NR: Homozy-
gous defect in HIV-1 coreceptor accounts for resistance of some
multiply-exposed individuals to HIV-1 infection. Cell 86:367–377,
1996
24. SAMSON M, LIBERT F, DORANZ BJ, RUCKER J, LIESNARD C, FARBER
CM, SARAGOSTI S, LAPOUMEROULIE C, COGNAUX J, FORCEILLE C,
MUYLDERMANS G, VERHOFSTEDE C, BURTONBOY G, GEORGES M,
IMAI T, RANA S, YI Y, SMYTH RJ, COLLMAN RG, DOMS RW, VASSART
G, PARMENTIER M: Resistance to HIV-1 infection in caucasian
individuals bearing mutant alleles of the CCR-5 chemokine receptor
gene. Nature 382:722–725, 1996
25. MICHAEL NL, CHANG G, LOUIE LG, MASCOLA JR, DONDERO D, BIRX
DL, SHEPPARD HW: The role of viral phenotype and CCR-5 gene
defects in HIV-1 transmission and disease progression. Nature Med
3:338–40, 1997
26. D’AGATI V, APPEL GB: HIV infection and the kidney. J Am Soc
Nephrol 8:138–152, 1997
27. RAO TK: Renal complications in HIV disease. Med Clin North Am
80:1437–1451, 1996
28. HUMPHREYS MH: Human immunodeficiency virus-associated glomer-
ulosclerosis. Kidney Int 48:311–320, 1995
29. ALPERS CE, TSAI CC, HUDKINS KL, CUI Y, KULLER L, BENVENISTE
RE, WARD JM, MORTON WR: Focal segmental glomerulosclerosis in
primates infected with a simian immunodeficiency virus. AIDS Res
Hum Retroviruses 13:413–424, 1997
30. WATSON A, MCCLURE J, RANCHALIS J, SCHEIBEL M, SCHMIDT A,
KENNEDY B, MORTON WR, HAIGWOOD NL, HU SL: Early postinfec-
tion antiviral treatment reduces viral load and prevents CD41 cell
decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses
13:1375–1381, 1997
31. AGY MB, FRUMKIN LR, COREY L, COOMBS RW, WOLINSKY SM,
KOEHLER J, MORTON WR, KATZE MG: Infection of Macaca nemes-
trina by human immunodeficiency virus type-1. Science 257:103–106,
1992
32. FRUMKIN LR, AGY MB, COOMBS RW, PANTHER L, MORTON WR,
KOEHLER J, FLOREY MJ, DRAGAVON J, SCHMIDT A, KATZE MG,
COREY L.: Acute infection of Macaca nemestrina by human immuno-
deficiency virus type 1. Virology 195:422–431, 1993
33. LANDAU NR, LITTMAN DR: Packaging system for rapid production of
murine leukemia virus vectors with variable tropism. J Virol 66:5110–
5113, 1992
34. MORGENSTERN JP, LAND H: Advanced mammalian gene transfer:
High titre retroviral vectors with multiple drug selection markers and
a complementary helper-free packaging cell line. Nucleic Acids Res
18:3587–3596, 1990
35. ALPERS CE, HUDKINS KL, DAVIS CL, MARSH CL, RICHES W, MC-
CARTY JM, BENJAMIN CD, CARLOS TM, HARLAN JM, LOBB R:
Expression of vascular cell adhesion molecule-1 in kidney allograft
rejection. Kidney Int 44:805–816, 1993
36. ALPERS CE, DAVIS CL, BARR D, MARSH CL, HUDKINS KL: Identifi-
cation of platelet-derived growth factor A and B chains in human
renal vascular rejection. Am J Pathol 148:439–451, 1996
37. TAUB DD: Chemokine-leukocyte interactions. The voodoo that they
do so well. Cytokine Growth Factor Rev 7:355–376, 1996
38. STRIETER RM, STANDIFORD TJ, HUFFNAGLE GB, COLLETTI LM,
LUKACS NW, KUNKEL SL: “The good, the bad, and the ugly.” The role
of chemokines in models of human disease. J Immunol 156:3583–3586,
1996
39. PREMACK BA, SCHALL TJ: Chemokine receptors: Gateways to inflam-
mation and infection. Nature Med 2:1174–1178, 1996
40. ROTTMAN JB, GANLEY KP, WILLIAMS K, WU L, MACKAY CR,
RINGLER DJ: Cellular localization of the chemokine receptor CCR5.
Correlation to cellular targets of HIV-1infection. Am J Pathol 151:
1341–1351, 1997
41. SCHADDE E, KRETZLER M, BANAS B, LUCKOW B, ASSMAN KJM,
SCHLO¨NDORFF D: Chemokine receptor 1 to 5 expression in mouse
anti-GBM-nephritis. (abstract) J Am Soc Nephrol 8:485A, 1997
42. NADEAU KC, AZUMA H, TILNEY NL: Sequential cytokine dynamics in
chronic rejection of rat renal allografts: Roles for cytokines RANTES
and MCP-1. Proc Natl Acad Sci USA 92:8729–8733, 1995
43. GRANDALIANO G, GESUALDO L, RANIERI E, MONNO R, STALLONE G,
SCHENA FP: Monocyte chemotactic peptide-1 expression and mono-
cyte infiltration in acute renal transplant rejection. Transplantation
63:414–420, 1997
44. COCCHI F, DEVICO AL, GARZINO-DEMO A, ARYA SK, GALLO RC,
LUSSO P: Identification of RANTES, MIP-1 alpha. and MIP-1beta as
the major HIV- suppressive factors produced by CD81 T cells.
Science 270:1811–185, 1995
45. BLEUL CC, FARZAN M, CHOE H, PAROLIN C, CLARK-LEWIS I, SO-
DROSKI J, SPRINGER TA: The lymphocyte chemoattractant SDF-1 is a
ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829–833,
1996
46. OBERLIN E, AMARA A, BACHELERIE F, BESSIA C, VIRELIZIER JL,
ARENZANA-SEISDEDOS F, SCHWARTZ O, HEARD JM, CLARK-LEWIS I,
LEGLER DF, LOETSCHER M, BAGGIOLINI M, MOSER B: The CXC
chemokine SDF-1 is the ligand for LESTR/fusin and prevents infec-
tion by T-cell-line-adapted HIV-1. Nature 382:833–835, 1996
47. HUANG Y, PAXTON WA, WOLINSKY SM, NEUMANN AU, ZHANG L, HE
T, KANG S, CERADINI D, JIN Z, YAZDANBAKHSH K, KUNSTMAN K,
ERICKSON D, DRAGON E, LANDAU NR, PHAIR J, HO DD, KOUP RA:
The role of a mutant CCR5 allele in HIV-1 transmission and disease
progression. Nature Med 2:1240–1243, 1996
48. DEAN M, CARRINGTON M, WINKLER C, HUTTLEY GA, SMITH MW,
ALLIKMETS R, GOEDERT JJ, BUCHBINDER SP, VITTINGHOFF E, GOMP-
ERTS E, DONFIELD S, VLAHOV D, KASLOW R, SAAH A, RINALDO C,
DETELS R, SJ OB: Genetic restriction of HIV-1 infection and progres-
sion to AIDS by a deletion allele of the CKR5 structural gene. Science
273:1856–1862, 1996
49. KATZENSTEIN TL, EUGEN-OLSEN J, HOFMANN B, BENFIELD T, PED-
ERSEN C, IVERSEN AK, SORENSEN AM, GARRED P, KOPPELHUS U,
SVEJGAARD A, GERSTOFT J: HIV-infected individuals with the CCR
delta32/CCR5 genotype have lower HIV RNA levels and higher CD4
cell counts in the early years of the infection than do patients with the
wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune
Defic Syndr Hum Retrovirol 16:10–14, 1997
50. COHEN AH, SUN NC, SHAPSHAK P, IMAGAWA DT: Demonstration of
human immunodeficiency virus in renal epithelium in HIV-associated
nephropathy. Mod Pathol 2:125–128, 1989
51. PARDO V, SHAPSHAK P, YOSHIOKA M, STRAUSS J: HIV associated
nephropathy (HIVAN): Direct renal invasion or indirect glomerular
involvement? (abstract) FASEB J 5:A907, 1991
52. BARBIANO DI BELGIOJOSO G, GENDERINI A, VAGO L, PARRAVICINI C,
BERTOLI S, LANDRIANI N: Absence of HIV antigens in renal tissue
from patients with HIV-associated nephropathy. Nephrol Dial Trans-
plant 5:489–492, 1990
53. ALPERS CE, MCCLURE J, BURSTEN SL: Human mesangial cells are
resistant to productive infection by multiple strains of human immu-
nodeficiency virus types 1 and 2. Am J Kidney Dis 19:126–130, 1992
54. GREEN DF, RESNICK L, BOURGOIGNIE JJ: HIV infects glomerular
endothelial and mesangial but not epithelial cells in vitro. Kidney Int
41:956–960, 1992
Eitner et al: CCR5 expression in the kidney1954
